An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets Manufactured At Brooklyn, New York Versus At Barceloneta, Puerto Rico In Healthy Subjects

NCT00550329 COMPLETED

The objective of this study is to determine the bioequivalence of Glipizide GITS (Glucotrol XL) 2.5 mg tablets manufactured at the Brooklyn, New York facility versus tablets manufactured at the facility in Barceloneta, Puerto Rico.

Details

Lead sponsor	Pfizer
Status	COMPLETED
Enrolment	32
Start date	2007-10
Completion	2007-11

Conditions

• Diabetes Mellitus, Non-Insulin-Dependent
• Hyperglycemia

Interventions

• Glipizide GITS

Countries

Singapore